ExodusPoint Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

ExodusPoint Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-23,000	Closed	-$3.03M	–	2091
2025 Q1	$3.03M	Buy	+23,000	New	+$2.87M	0.03%	557

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

ExodusPoint Capital Management's ITCI Position: Q2 2025 in Review

ExodusPoint Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 18,843 shares — an estimated $2.49M sold.

ExodusPoint Capital Management first reported a position in ITCI in Q2 2019 and held it in 10 quarters. The position peaked at $2.53M in Q2 2023. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

ExodusPoint Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
ExodusPoint Capital Management sold 18,843 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $2.49M.
ExodusPoint Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2019 and held it in 10 quarters.
ExodusPoint Capital Management's Intra-Cellular Therapies Inc. position peaked at $2.53M in Q2 2023.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.